Santhera Pharmaceuticals Holding AG announced that it has entered into an equity-linked financing arrangement with IRIS (France) in the initial gross amount of up to CHF 12 million over 12 months, with the option to extend by another CHF 12 million over another 12 months. This innovative financing instruments provides Santhera with a liquidity line which can be tapped if certain conditions are satisfied.